PVLA logo

PVLA Palvella Therapeutics, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$148.68
+2.10 (+1.43%)

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcy…

Market Cap: $2.17Bpalvellatx.com

Price

No data yet.

Social Signal Score

55
5d
50
3 mentions
—
30d
57
9 mentions
—
60d
56
13 mentions
—
90d
55
16 mentions
—
news: 16

Analyst Ratings

12 analysts
Buyconsensus
Strong Buy 1Buy 11Hold 0Sell 0Strong Sell 0
Avg price target$230.2+54.8%
Low $207Median $232High $246
Current Consensus

Revenue

$0.00-100.00%
$0.00$6.68M$13.37M$20.05M
Mar 2023Sep 2026

Analyst Estimates

FY2025
$-3.52
$-3.72–$-2.89
11 analysts
FY2026
$-6.30
$-7.08–$-4.88
11 analysts
FY2027
$-7.98
$-12.48–$-3.40
11 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Wesley H. Kaupinen
Sector
Healthcare
Industry
Biotechnology
Employees
29
Beta
-0.17
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
29.73
palvellatx.com